rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?

Liebau, Christian; Merk, Harry; Roesel, Christian; Schmidt, Sebastian; Karreman, Christiaan; Prisack, Johannes Bernd; Bojar, Hans; Baltzer, Axel W. A.

rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2002

Autor:innen

Liebau, Christian

Merk, Harry

Roesel, Christian

Schmidt, Sebastian

Karreman, Christiaan

Prisack, Johannes Bernd

Bojar, Hans

Baltzer, Axel W. A.

Sammlungen

Biologie

Publikationstyp

Zeitschriftenartikel

Publikationsstatus

Published

Erschienen in

Anticancer Research. 2002, 22(5), pp. 2559-2565. ISSN 0250-7005. eISSN 1791-7530

Zusammenfassung

Gene therapy is a promising new method to treat tumors locally. Immuno-therapy for treatment of osteosarcomas is one option for hopefully improving the survival rate of patients with this tumor. Transduction of OS cells with the pCMV-IL-12neo plasmid induced a significant increase in IFN-gamma expression by mononuclear cells. This is known to induce antitumor effects mediated by the immune system. In combination with an administration of rIL-18, the IFN-gamma increase was multiplied in a dose-dependent manner. This study demonstrated that osteosarcoma cells can be targeted effectively in vitro by plasmids encoding the IL-12 gene. Considering the synergistic pathways it is reasonable to combine a local, gene transfer based on IL-12 with a rIL-18 administration to trigger the potentially promising immuno-effects for adjuvant treatment of osteosarcomas.

Fachgebiet (DDC)

570 Biowissenschaften, Biologie

Zitieren

ISO 690

LIEBAU, Christian, Harry MERK, Christian ROESEL, Sebastian SCHMIDT, Christiaan KARREMAN, Johannes Bernd PRISACK, Hans BOJAR, Axel W. A. BALTZER, 2002. rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?. In: Anticancer Research. 2002, 22(5), pp. 2559-2565. ISSN 0250-7005. eISSN 1791-7530

BibTex

@article{Liebau2002rIL18-38814,
  year={2002},
  title={rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?},
  number={5},
  volume={22},
  issn={0250-7005},
  journal={Anticancer Research},
  pages={2559--2565},
  author={Liebau, Christian and Merk, Harry and Roesel, Christian and Schmidt, Sebastian and Karreman, Christiaan and Prisack, Johannes Bernd and Bojar, Hans and Baltzer, Axel W. A.}
}

RDF

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/38814">
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/38814"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dc:date>
    <dcterms:title>rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?</dcterms:title>
    <dc:contributor>Roesel, Christian</dc:contributor>
    <dc:contributor>Merk, Harry</dc:contributor>
    <dc:contributor>Schmidt, Sebastian</dc:contributor>
    <dc:creator>Schmidt, Sebastian</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Liebau, Christian</dc:creator>
    <dc:creator>Bojar, Hans</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:issued>2002</dcterms:issued>
    <dc:language>eng</dc:language>
    <dc:creator>Karreman, Christiaan</dc:creator>
    <dc:contributor>Liebau, Christian</dc:contributor>
    <dc:contributor>Bojar, Hans</dc:contributor>
    <dc:contributor>Karreman, Christiaan</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dcterms:available>
    <dc:creator>Baltzer, Axel W. A.</dc:creator>
    <dc:contributor>Prisack, Johannes Bernd</dc:contributor>
    <dc:creator>Roesel, Christian</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Baltzer, Axel W. A.</dc:contributor>
    <dcterms:abstract xml:lang="eng">Gene therapy is a promising new method to treat tumors locally. Immuno-therapy for treatment of osteosarcomas is one option for hopefully improving the survival rate of patients with this tumor. Transduction of OS cells with the pCMV-IL-12neo plasmid induced a significant increase in IFN-gamma expression by mononuclear cells. This is known to induce antitumor effects mediated by the immune system. In combination with an administration of rIL-18, the IFN-gamma increase was multiplied in a dose-dependent manner. This study demonstrated that osteosarcoma cells can be targeted effectively in vitro by plasmids encoding the IL-12 gene. Considering the synergistic pathways it is reasonable to combine a local, gene transfer based on IL-12 with a rIL-18 administration to trigger the potentially promising immuno-effects for adjuvant treatment of osteosarcomas.</dcterms:abstract>
    <dc:creator>Merk, Harry</dc:creator>
    <dc:creator>Prisack, Johannes Bernd</dc:creator>
  </rdf:Description>
</rdf:RDF>

Universitätsbibliographie

Nein